potential of miRNA as a complementary biomarker in a defined PE collective (late-onset: ≥34 +0 weeks of gestation).Methods: This interim analysis of a single-centre, prospective cohort study compares patients with confirmed late-onset PE (n = 8) with healthy controls (n = 8).The concentration of the most common PE-associated miRNAs in maternal serum was examined (miR-210, miR-518b, miR-221).PE pregnancies were further subdivided into angiogenic (≥110) and non-angiogenic (<110) based on the sFlt-1/PlGF ratio.Due to the small number of cases, a purely descriptive statistical analysis was carried out.Results: The mean gestational age in the PE and control group was 37 +0 weeks' gestation.The following mean concentrations (delta CT) could be detected in the PE group vs. control group: miR-210 (7.76 vs. 8.00), miR-518b (9.39 vs. 10.11) and miR-221 (13.41 vs. 12.06).A subdivision into non-angiogenic (sFlt-1/PlGF <110) vs. angiogenic PE (sFlt-1/PlGF ≥110) revealed the following concentration differences within the PE group: miR-210 (7.14 vs. 8.13), miR-518b (9.68 vs. 9.21) and miR-221 (12.19 vs. 14.14).Conclusions: There were no significant miRNA concentration differences between late-onset PE cases and controls.However, the extent to which there are concentration differences in cases with early-onset PE (and a greater extent of an anti-angiogenic imbalance) needs to be clarified in future studies.